Cardinal Health has entered an agreement with Trubion Pharmaceuticals, Inc. to research a new method to rapidly produce biopharmaceuticals that are smaller than traditional protein-based medicines. Many traditional biopharmaceuticals are monoclonal antibodies (mAbs) made up of long-chain proteins that can sometimes fail to reach their targets due to their size. Trubion’s proprietary Small Modular Immunopharmacetical (SMIP) drug design technology creates drug candidates of single-chain...